Artwork
iconShare
 
Manage episode 513760445 series 3645695
Content provided by Joe Brunetto. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Joe Brunetto or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode of WTR Healthcare Happenings, host Tim Gerdeman and WTR’s Robert Sassoon speak with Amit Kumar, PhD, CEO of Anixa Biosciences (NASDAQ: ANIX) to discuss t-cells and Anixa's two clinical developments, one involving the modification of CAR-T technology to overcome the challenges of treating solid tumors, specifically ovarian cancer, and the other, an innovative breast cancer vaccine that trains antigen-specific t-cells to recognize and attack breast cancer cells, especially those from triple-negative breast cancer, the most aggressive form of breast cancer. Kumar also talks about the company's robust balance sheet and financial strategy to advance Anixa's clinical developments to commercialization.

  continue reading

23 episodes